We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.
Information on how the voluntary scheme for branded medicines pricing, access and growth (VPAG) is controlling spend on branded medicines in the NHS.
These published standards relate to a number of KPIs in the VMD Deliverables and KPI document.
Minutes of meetings held between the government, NHS England and ABPI about the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG).
Information on how the voluntary scheme for branded medicines pricing and access is controlling spend on branded medicines in the NHS.
Incorporation of ‘social’ variables into epidemiological models remains a challenge
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).